ArticleTargeted oncology2024

ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study.

Michael Maris et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.